SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Battiwalla Minoo)
 

Sökning: WFRF:(Battiwalla Minoo) > (2020) > Kharfan Dabaja Mohamed A. > Age no bar :

Age no bar : A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

Munshi, Pashna N. (författare)
MedStar Georgetown Univ Hosp, Washington, DC USA.
Vesole, David (författare)
Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA.
Jurczyszyn, Artur (författare)
Jagiellonian Univ Med Coll, Dept Hematol, Krakow, Poland.;Krakow Branch Polish Soc Haematol & Blood Transfu, Krakow, Poland.
visa fler...
Zaucha, Jan Maciej (författare)
Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland.
St Martin, Andrew (författare)
Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
Davila, Omar (författare)
Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
Agrawal, Vaibhav (författare)
Indiana Univ Sch Med, Div Hematol Oncol, Indianapolis, IN 46202 USA.
Badawy, Sherif M. (författare)
Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol & Stem Cell Transplant, Chicago, IL USA.;Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA.
Battiwalla, Minoo (författare)
Sarah Cannon Blood Canc Network, Nashville, TN USA.
Chhabra, Saurabh (författare)
Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.
Copelan, Edward (författare)
Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA.
Kharfan-Dabaja, Mohamed A. (författare)
Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL USA.
Farhadfar, Nosha (författare)
Univ Florida, Div Hematol Oncol, Coll Med, Gainesville, FL USA.
Ganguly, Siddhartha (författare)
Univ Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA.
Hashmi, Shahrukh (författare)
Mayo Clin, Dept Internal Med, Rochester, MN USA.;King Faisal Specialist Hosp & Res Ctr, Ctr Oncol, Riyadh, Saudi Arabia.
Krem, Maxwell M. (författare)
Univ Kentucky, Markey Canc Ctr, Coll Med, Lexington, KY USA.
Lazarus, Hillard M. (författare)
Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA.
Malek, Ehsan (författare)
Univ Hosp Cleveland, Seidman Canc Ctr, Med Ctr, Cleveland, OH 44106 USA.
Meehan, Kenneth (författare)
DartmouthHitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH USA.
Murthy, Hemant S. (författare)
Nishihori, Taiga (författare)
H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.
Olin, Rebecca L. (författare)
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Olsson, Richard F. (författare)
Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden.
Schriber, Jeffrey (författare)
Virginia G Piper Canc Ctr, Canc Transplant Inst, Scottsdale, AZ USA.;Arizona Oncol, Scottsdale, AZ USA.
Seo, Sachiko (författare)
Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.
Shah, Gunjan (författare)
Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY USA.
Solh, Melhem (författare)
Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.
Tay, Jason (författare)
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Kumar, Shaji (författare)
Mayo Clin Rochester, Dept Hematol, Rochester, MN USA.
Qazilbash, Muzaffar H. (författare)
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Shah, Nina (författare)
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Hari, Parameswaran N. (författare)
Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
D'Souza, Anita (författare)
Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
visa färre...
MedStar Georgetown Univ Hosp, Washington, DC USA Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA. (creator_code:org_t)
2020-09-23
2020
Engelska.
Ingår i: Cancer. - : WILEY. - 0008-543X .- 1097-0142. ; 126:23, s. 5077-5087
Relaterad länk:
https://www.ncbi.nlm...
visa fler...
https://urn.kb.se/re...
https://doi.org/10.1...
http://kipublication...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults. Methods The authors investigated the outcomes of AHCT in patients with MM who were aged >= 70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged >= 70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, aPvalue <.01 was considered to be statistically significant a priori. Results An increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged >= 70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m(2)overall, 58% of the patients aged >= 70 years received Mel at a dose of 140 mg/m(2). On multivariate analysis, patients aged >= 70 years demonstrated no difference with regard to NRM (hazard ratio [HR] 1.3; 99% confidence interval [99% CI], 1-1.7 [P = .06]), REL (HR, 1.03; 99% CI, 0.9-1.1 [P = 0.6]), PFS (HR, 1.06; 99% CI, 1-1.2 [P = 0.2]), and OS (HR, 1.2; 99% CI, 1-1.4 [P = .02]) compared with the reference group (those aged 60-69 years). In patients aged >= 70 years, Mel administered at a dose of 140 mg/m(2)was found to be associated with worse outcomes compared with Mel administered at a dose of 200 mg/m(2), including day 100 NRM (1% [95% CI, 1%-2%] vs 0% [95% CI, 0%-1%];P = .003]), 2-year PFS (64% [95% CI, 60%-67%] vs 69% [95% CI, 66%-73%];P = .003), and 2-year OS (85% [95% CI, 82%-87%] vs 89% [95% CI, 86%-91%];P = .01]), likely representing frailty. Conclusions The results of the current study demonstrated that AHCT remains an effective consolidation therapy among patients with MM across all age groups.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

age
geriatric oncology
myeloma
transplantation

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy